Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $7.66
Previous CloseN/A
Volume165.25K
Average Volume (3M)1.18M
Market Cap
$115.03M
Enterprise Value$75.03M
Total Cash (Recent Filing)$89.66M
Total Debt (Recent Filing)$69.72M
Price to Earnings (P/E)―
Beta3.57
Next Earnings
May 08, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding71,007,080
10 Day Avg. Volume1,693,620
30 Day Avg. Volume1,184,250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.77
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$11.88Price Target Upside651.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
C4 Therapeutics News
PremiumCompany Announcements
C4 Therapeutics Board Member Bruce Downey Retires
PremiumCompany Announcements
C4 Therapeutics Outlines 2025 Milestones and Achievements
---
Bulls Say, Bears Say
Bulls Say
Growth OpportunityThe company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.
Partnership PotentialManagement intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.
Product DevelopmentCFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.
Bears Say
Partnership UncertaintyCCCC has expressed its intent to partner the cemsidomide program, but a partnership has not yet been announced.
Regulatory UncertaintyOngoing discussions with regulators could pave the way for market approval of cemsidomide.
Safety ConcernsThere were notable Grade 3 or higher treatment-related adverse events, such as neutropenia and anemia.
---
Ownership Overview
3.13% Insiders
14.78% Mutual Funds
0.33% Other Institutional Investors
71.81% Public Companies and
Individual Investors
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.08 and its highest was $7.66 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $115.03M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 7 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.493 by $0.003.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 71,007,080 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.493. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
---
C4 Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.88 (651.90% Upside)
$11.88 (651.90% Upside)
Blogger Sentiment
Neutral
CCCC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 21.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.00%
12-Months-Change
Fundamentals
Return on Equity
-45.58%
Trailing 12-Months
Asset Growth
-7.13%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
---
CCCC Stock 12 Month Forecast
Average Price Target
$11.88
▲(651.90% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
Vor Biopharma
―
Climb Bio
―
Zura Bio
―
Kyverna Therapeutics, Inc.
―
---